1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,636 | 0,640 | 03.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 48,950 | -2,18 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 204,80 | +0,15 % | Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | ||
| ARBUTUS BIOPHARMA | 3,630 | -1,09 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| MUSTGROW BIOLOGICS | 0,320 | -9,60 % | Bayer, MustGrow Biologics, K+S - die geheime Gewinnformel hinter der biologischen Dünger-Revolution | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Düngemittelbranche durchläuft ihren bedeutendsten Strukturwandel seit Generationen. Steigende Weltbevölkerung, technologische... ► Artikel lesen | |
| VERICEL | 28,000 | -6,04 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,470 | +0,41 % | Moleculin Biotech, Inc.: Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits | ||
| SENSEI BIOTHERAPEUTICS | 15,590 | -3,14 % | Sensei Biotherapeutics, Inc. - 10-K/A, Annual Report | ||
| BIOXCEL THERAPEUTICS | 1,040 | +0,97 % | BioXcel presents data on at-home agitation treatment trial | ||
| REGENXBIO | 5,634 | +0,43 % | REGENXBIO Inc. - 8-K, Current Report | ||
| AKEBIA | 0,808 | +0,30 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ZEVRA THERAPEUTICS | 9,660 | +3,21 % | Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US | ||
| FENNEC PHARMACEUTICALS | 8,300 | 0,00 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK at the 2026 ASCO Annual Meeting | - Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK- (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations - - Real-World Evidence... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 9,878 | -1,61 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors | SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D.,... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,200 | -18,11 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 | Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial flexibility... ► Artikel lesen | |
| NANOBIOTIX | 30,000 | -2,22 % | Nanobiotix S.A.: Nanobiotix Provides First Quarter 2026 Operational and Financial Update | Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew... ► Artikel lesen |
SYNTHAVERSE SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,004 (-0,63 %) liegt der Kurs bei 0,633 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.